CTRI/2010/091/000494已完成3 期
A Phase 3, Multi-centric, Single blind, Randomized, Comparative study to assess the efficacy and safety of fixed dose combination of Telmisartan + Amlodipine + Hydrochlorothiazide bi-layered tablet verses Telmisartan + Hydrochlorothiazide tablet for the treatment in patients with essential hypertension
Aristo Pharmaceuticals Pvt Ltd0 个研究点目标入组 220 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Males or Females with essential hypertension (SBP 140-200 mmHg DBP 90-120 mmHg), age >18 yrs, wiiling to follow up and informed consent, etc
排除标准
- •Pregnant, lactating women, secondary hypertension,uncontrolled diabetes, etc
研究者
相似试验
招募中
3 期
Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection due to Carbapenem-Resistant Enterobacterales2024-515180-56-00Meiji Seika Pharma Co. Ltd.96
招募中
3 期
P3 Study to assess efficacy and safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection due to Carbapenem Resistant EnterobacteralesJPRN-jRCT2031230076Suwada Keisuke150
进行中（未招募）
1 期
Safety and immunogenicity of repeated annual exposure to the aQIV vaccine in children following vaccination in trials V118_05 and V118_05E1Prophylaxis for influenza virusMedDRA version: 18.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-003008-22-FIovartis Pharma Services AG486
已完成
3 期
A clinical trial to study the efficacy and safety of Montelukast and Fexofenadine fixed dose combination tablet Versus Fexofenadine tablet alone in the patients of Allergic Rhinitis.CTRI/2010/091/001300upin Limited India220
未知
3 期
A Phase 3, Long-Term Study of TAK-438 (10 and 20 mg) in the Maintenance Treatment of Healed Erosive EsophagitisErosive esophagitisJPRN-jRCT2080221575TAKEDA PHARMACEUTICAL COMPANY LTD.300